MI
ZVRA icon

Motiv8 Investments’s Zevra Therapeutics ZVRA Stock Holding History

Motiv8 Investments’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$0 Buy
+25
New +$236 ﹤0.01% 992

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Motiv8 Investments's ZVRA Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Zevra Therapeutics (ZVRA) in Q4 2025: 25 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #992 among its holdings.

158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Motiv8 Investments held 25 shares of Zevra Therapeutics worth $0 as of Q4 2025.
  • Zevra Therapeutics was a new Motiv8 Investments position in Q4 2025.
  • Zevra Therapeutics made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #992 holding.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.